Progress of neoadjuvant therapy for high-risk prostate cancer in the era of novel hormonal therapy / 现代泌尿外科杂志
Journal of Modern Urology
; (12): 1092-1096, 2023.
Article
en Zh
| WPRIM
| ID: wpr-1005947
Biblioteca responsable:
WPRO
ABSTRACT
In the past, the use of neoadjuvant androgen deprivation therapy (ADT) for prostate cancer did not exhibit survival benefits and was not recommended by the practicing guidelines. In recent years, with the emergence of novel hormonal therapeutics such as Abiraterone, Enzalutamide, Apalutamide and Darolutamide, the interest for neoadjuvant therapy has been reignited. Here, we summarize the four categories of neoadjuvant therapy with new hormonal agents, and discuss how to evaluate the efficacy and explore the molecular mechanism after neoadjuvant therapy.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of Modern Urology
Año:
2023
Tipo del documento:
Article